RNAi specialist ADARx Pharmaceuticals raised $446.3 million in its initial public offering Thursday, pricing 26.25 million shares at $17 each, the ceiling of its marketed range, and adding an $89 million private placement from development partner AbbVie. The stock begins trading Friday on Nasdaq under the ticker ADRX, giving the company a rare public currency in a sector that has largely avoided traditional listings for more than a decade.
The structure is clean but thin on detail
The offering consists entirely of primary shares, with no selling stockholders, and the underwriting syndicate includes a standard 15 percent overallotment option that could lift gross proceeds to roughly $513 million. The filing does not disclose a break fee or minimum funding condition tied to the AbbVie private placement, which priced at the same $17 per share. AbbVie’s participation extends a relationship that began last year with a $335 million upfront payment for codevelopment rights across neurology, immunology and oncology, a deal that now looks like a de facto anchor for the IPO.
Pipeline value rests on a single late-stage asset
ADARx’s most advanced program, onvuzosiran, targets hereditary angioedema and is in Phase 3 testing with data expected by the end of 2027. The company claims the drug could be dosed as infrequently as twice a year and showed up to 93 percent reduction in plasma kallikrein in early studies. A second candidate, agazisiran, is positioned as a pipeline-in-a-product across kidney disease, geographic atrophy and paroxysmal nocturnal hemoglobinuria, with earlier programs aimed at stroke, obesity and neurological targets outside the liver. Every marketed RNAi drug to date has targeted the liver; ADARx’s extrahepatic ambitions remain unproven.
The IPO window is narrow and getting narrower
This is the first RNA-focused biotech to price a traditional U.S. IPO in nearly two years and the only RNAi company to do so in over a decade, according to BioPharma Dive data. Twenty-two drug developers have listed in 2026 so far, most of them small-molecule or biologics shops. Renaissance Capital notes that biotech has dominated new issuance volume at a pace not seen since 2021, but its latest quarterly review flags rising bond yields at a 19-year high, renewed rate-hike expectations and scrutiny of artificial intelligence spending as headwinds that could stall the pipeline of new offerings in the months ahead.
Four more filings signal the queue has not cleared
Despite the caution, four biotechs filed registration statements in the past week alone: fellow RNA developer City Therapeutics, AI-driven Iambic Therapeutics, immune-focused TRex Bio and one other unnamed company. Venture backers OrbiMed, Bain Capital, TCGX and Venrock collectively put more than $350 million into ADARx before the listing. Whether the public markets absorb this supply at current valuations will test if the AbbVie anchor represents conviction or simply a cost of maintaining optionality on the partnership.